[go: up one dir, main page]

WO2019004734A2 - Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif - Google Patents

Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2019004734A2
WO2019004734A2 PCT/KR2018/007320 KR2018007320W WO2019004734A2 WO 2019004734 A2 WO2019004734 A2 WO 2019004734A2 KR 2018007320 W KR2018007320 W KR 2018007320W WO 2019004734 A2 WO2019004734 A2 WO 2019004734A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
fatty liver
liver disease
active ingredient
rice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/007320
Other languages
English (en)
Korean (ko)
Other versions
WO2019004734A3 (fr
Inventor
채성욱
임아랑
김기모
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170181811A external-priority patent/KR102041852B1/ko
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2019004734A2 publication Critical patent/WO2019004734A2/fr
Publication of WO2019004734A3 publication Critical patent/WO2019004734A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Definitions

  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the death rate of domestic liver disease is very high at 23.5 people per 100,000 people.
  • the death rate is the highest in the 40s (41.1 people / 100,000 people), the second in the 50s (72.4 people / 100,000 people) (10 people / 100,000 people), including liver disease is the leading cause of death in the Korean middle-aged population.
  • liver diseases fatty liver suggests that abnormal fat, which is not present in normal cells, is abnormally deposited in liver cells.
  • abnormal fat which is not present in normal cells, is abnormally deposited in liver cells.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester
  • hepatocytes When the fatty liver becomes worse and fat mass in hepatocyte becomes larger, important components of the cells including nucleus are pushed to one side, the function of the hepatocyte is lowered, and the expanded hepatocytes due to the accumulated fat in the cells pressurize the microvascular and lymphatic vessels between the hepatocytes Resulting in obstacles to the circulation of blood and lymph in the liver. In this way, hepatocytes can not properly receive oxygen and nutrient supply, and liver function is deteriorated.
  • Non-alcoholic fatty liver disease is defined as the accumulation of fatty acids in the form of triglycerides in hepatic parenchymal cells by at least 5%, not by liver damage caused by alcohol. Pathologically, it is classified as simple steatosis and inflammatory fatty liver disease (steatohepatitis). It can be converted to severe liver disease such as hepatitis, liver fibrosis and cirrhosis when left for a long time. In Korea, the frequency of nonalcoholic liver disease is increasing due to changes in lifestyle.
  • Alcoholic fatty liver disease is caused by excessive alcohol consumption. Individuals have different genetic characteristics and gender. However, alcohol intake of 80g or more per day is likely to cause liver disease such as alcoholic fatty liver disease. Women are more likely to develop alcoholic liver disease in lesser amounts. Generally, it can be calculated that one cup of soju, one cup of beer, one cup of wine, and one cup of makkolli contain about 10 g of alcohol. The most mild form of alcoholic fatty liver disease is asymptomatic, but mild hepatic enlargement (greater than normal liver) may cause mild tenderness in the right upper abdomen.
  • the rice-grasshopper has a body length of 30 to 38 mm, the body color is yellow-green, and the head and chest are yellowish brown.
  • the compound eyes are egg-shaped and lustrous grayish brown.
  • the wings are yellowish brown and longer than the end of the boat but do not fly much. Inhabits grassy areas near rice fields and cultivated areas. It occurs once a year, and it drifts with a bunch of ground in the ground.
  • the alum is wrapped in a thin film of collagen.
  • the full-grown nymphs have a wing crest at the fourth node and a body length of about 30 mm.
  • the use of pesticides as a major pest of rice has decreased, but it is gradually increasing. In 1930, it originated in Hwanghae Province and bought eggs from the government. It is distributed in Korea, Japan, and China.
  • Korean Patent No. 1648812 discloses a method for producing a diet food composition containing a rice-grasshopper ingredient
  • Korean Patent Publication No. 2010-0002661 discloses a functional complex containing hyaluronic acid and a method for producing the same
  • a composition for preventing, improving or treating a fatty liver disease comprising the rice grasshopper extract of the present invention as an active ingredient.
  • the present invention provides a composition for preventing, ameliorating or treating a fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the present invention provides a composition for preventing, ameliorating or treating fatty liver disease, And the weight change of the animal model according to administration of the rice grasshopper extract; Weight change of liver, subcutaneous fat, kidney fat tissue and small intestine fat tissue; Confirming that lipid biochemical indicators change significantly, thus completing the present invention.
  • the present invention provides a health functional food composition for preventing or ameliorating fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the present invention also provides a pharmaceutical composition for preventing or treating fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the present invention also provides a veterinary composition for the prevention or treatment of fatty liver disease in an animal other than a human, comprising a rice grasshopper extract as an active ingredient.
  • the present invention provides a feed additive for preventing or ameliorating fatty liver disease in an animal other than a human, comprising a rice plant extract as an active ingredient.
  • the present invention also provides a method of preventing or treating fatty liver disease comprising administering a rice grasshopper extract to a subject other than a human.
  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease comprising a rice grasshopper extract as an active ingredient.
  • the rice grasshopper extract as an active ingredient of the present invention is free from side effects and toxicity , Hepatocellular carcinoma cell line (HepG 2 ), and the weight change of the animal model according to the administration of the rice grasshopper extract; Weight change of liver, subcutaneous fat, kidney fat tissue and small intestine fat tissue; Since changes in lipid biochemical indicators are significant, the composition of the present invention can be useful as a health functional food, a medicine, or a feed additive for prevention, improvement or treatment of fatty liver disease.
  • 1 is a liver cancer cell line (HepG 2) on oleate and palmitate is 2: 1 was treated with 1.0mM of the free fatty acids and byeomettugi extract mixed in a concentration ratio, Nile Red, the content of triglyceride (H depot red) staining of Respectively.
  • #### showed a statistically significant increase in nile red expression (%) in the 1.0 mM free fatty acid-treated group compared with the negative control (control) without 1.0 mM free fatty acid, and p ⁇ 0.0001
  • **** indicates that nile red expression decreased statistically in the group treated with free fatty acid and rice grasshopper extract compared with free fatty acid treatment group, and p ⁇ 0.0001.
  • FIG. 2 shows the results of measuring the content of total triglyceride after treating 1.0 mM of free fatty acid and rice grasshopper extract in which hepatocellular carcinoma cell line (HepG 2 ) was mixed at a concentration ratio of 2: 1 of oleate and palmitate.
  • HepG 2 hepatocellular carcinoma cell line
  • FIG. 3 shows the result of lipid uptake after treatment of 1.0 mM free fatty acid and rice grasshopper extract in which hepatocellular carcinoma cell line (HepG 2 ) was mixed with olate and palmitate at a concentration ratio of 2: 1.
  • #### indicates that the relative fat absorption rate was statistically significantly increased in the 1.0 mM free fatty acid-treated group compared to the negative control group without the 1.0 mM free fatty acid treatment (p ⁇ 0.0001)
  • **** indicates that the relative fat absorption rate was significantly decreased in the group treated with free fatty acid and rice plant extract compared to the free fatty acid treated group, and p ⁇ 0.0001.
  • FIG. 4 shows the results of confirming the cell viability (%) after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and rice horticultural extracts.
  • the cell survival rate (%) was statistically significantly decreased compared to the negative control (control) without treatment with 1.0 mM of free fatty acid, and p ⁇ 0.0001 ** indicates that the cell survival rate (%) was statistically significantly increased in the group treated with free fatty acid and rice plant extract compared to the free fatty acid treated group, ** indicates that p ≪ 0.01 and **** is p ⁇ 0.0001.
  • FIG. 5 shows the results of confirming the expression level of Caspase-3 after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and rice horticultural extracts.
  • control without 1.0 mM free fatty acid
  • #### showed a statistically significant increase in the relative Caspase-3 expression in the 1.0 mM free fatty acid-treated group, p ⁇ 0.0001, and **** indicates that the relative expression of Caspase-3 was significantly decreased in the group treated with free fatty acid and rice plant extract compared with the group treated with free fatty acid, and p ⁇ 0.0001.
  • FIG. 6 shows the result of confirming that the body weight increased by the high fat diet was reduced by administration of the rice plant extract.
  • FIG. 7 shows the results of confirming that liver, subcutaneous fat, kidney fat, and small intestine fat weight of mice increased by high fat diet decreased by the administration of the rice hatchlings extract.
  • ## means that the weight of liver, subcutaneous fat, kidney fat tissue and small intestine fat tissue of HFD was statistically significantly increased compared to that of normal diet (p ⁇ 0.0001) *, ***, and **** were statistically significantly higher than those of the high-fat diet group and the high fat diet group and the rice horticultural extract group (MTG), respectively.
  • FIG. 8 shows the results of confirming that ALT and AST in the blood of the mice increased by the high-fat diet were decreased by administration of the rice-grasshopper extract.
  • ALT GPT
  • AST GOT
  • M100 indicates a positive control group And milk seeds.
  • FIG. 9 shows the results of confirming that the concentration of triglyceride, total cholesterol, low density lipoprotein, and free fatty acid in the blood of the mice increased by the high fat diet decreased by the administration of the rice hogger extract.
  • P ⁇ 0.0001, indicating that the triglyceride, total cholesterol, low density lipoprotein and free fatty acid concentrations of the high fat diet group (HFD) were statistically significantly increased compared to the normal diet (Nor) , ** and *** were significantly higher than those of the high fat diet group and the high fat diet group and the rice hunting group (MTG) * Indicates p ⁇ 0.05, ** indicates p ⁇ 0.01, *** indicates p ⁇ 0.001, and M100 is a positive control, milk seed.
  • HFD high fat diet group
  • M100 is a positive control, milk seed.
  • FIG. 10 shows the results of confirming that the blood glucose concentration of the mice increased by the high fat diet decreased by the administration of the rice plant extract.
  • HFD blood glucose level in the high-fat diet group
  • Nor normal diet group
  • p ⁇ 0.0001 and * and *** are high fat diet group
  • *** was p ⁇ 0.001, respectively, as compared with the high fat diet group and the high fat diet group (MTG)
  • M100 is a positive control, milk seeds.
  • the present invention relates to a health functional food composition for preventing or ameliorating fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the rice plant extract may be produced by a method including, but not limited to, the following steps:
  • step (3) The step of extracting the filtered extract of step (2) by concentration under reduced pressure and drying.
  • the extraction solvent is preferably selected from water, a C 1 -C 4 lower alcohol or a mixture thereof, more preferably a C 1 -C 4 lower alcohol, still more preferably 70% (v / v) ethanol, but is not limited thereto.
  • any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used.
  • the extraction solvent is preferably added by 1 to 20 times the weight of the dried rice hogger, more preferably 5 to 15 times.
  • the extraction temperature is preferably 4 to 50 ° C, but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but not always limited thereto.
  • the drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
  • the fatty liver disease is non-alcoholic or alcoholic simple fatty liver; Non-alcoholic or alcoholic fatty liver disease; And non-alcoholic or alcoholic cirrhosis, but is not limited thereto.
  • the rice plant extracts are characterized by reducing the content of triglyceride in liver tissue, reducing the content of total triglyceride in liver tissue and decreasing lipid uptake.
  • the health functional food may be prepared by adding the composition of the present invention to a food for the purpose of preventing or ameliorating fatty liver disease.
  • the health functional food is not particularly limited, and may be a health functional food, a nutritional supplement, but it can be any type of food such as pharmafood, health food, nutraceutical, designer food, food additive, etc.
  • the food can be meat, sausage, bread, chocolate, candy, snack, confectionery, , Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes.
  • the method of adding is appropriately used according to a conventional method, and the amount to be added can be suitably determined according to the intended use (prevention, health or therapeutic treatment).
  • composition of the present invention may further include various components other than the active component.
  • the various components may be various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, Salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. It may also contain flesh for the production of natural fruit juices, fruit juice beverages and vegetable beverages to add palatability and / or functionality, and these ingredients may be used independently or in combination.
  • the present invention also relates to a pharmaceutical composition for preventing or treating fatty liver disease comprising an extract of a rice plant as an active ingredient.
  • the pharmaceutical compositions of the present invention may comprise a pharmaceutically acceptable carrier.
  • the pharmacologically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one which is usually used at the time of formulation and includes saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, But are not limited to, cellulose, sucrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrup, methylcellulose, methylhydroxybenzoate, Hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further comprise an antioxidant, a buffer, a bacteriostatic agent, a diluent, a surfactant, a binder, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent or a preservative.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered orally.
  • the appropriate dosage of the pharmaceutical composition of the present invention may vary depending on such factors as formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, .
  • the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg on an adult basis.
  • the pharmaceutical composition of the present invention may be formulated into a unit dosage form by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container.
  • the formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
  • the present invention also relates to a veterinary composition for the prevention or treatment of fatty liver disease in an animal other than a human, comprising a rice grasshopper extract as an active ingredient.
  • the veterinary composition comprising the rice grasshopper extract of the present invention may further comprise suitable excipients and diluents according to conventional methods.
  • excipients and diluents that can be included in the veterinary composition containing the rice grasshopper extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium But are not limited to, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, Sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
  • the veterinary composition comprising the rice grasshopper extract according to the present invention may further contain a filler, an anti-coagulant, a lubricant, a wetting agent, a spice, an emulsifier and an antiseptic agent. And may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the composition, and the formulations may be formulated as powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, Or hard gelatin capsules, suppositories, sterile injectable solutions, sterile external preparations, and the like.
  • the veterinary composition according to the present invention may vary depending on the age, sex, and body weight of the animal, but may be administered in an amount of 0.1 to 100 mg / kg once or several times a day.
  • the dosage may vary depending on the route of administration, Sex, weight, age, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
  • the present invention also relates to a feed additive for preventing or ameliorating fatty liver disease in an animal other than a human, which comprises a rice grasshopper extract as an active ingredient.
  • the feed additive may be in the form of a high concentrate, powder or granulate containing 20 to 90% by weight of the grasshopper extract.
  • the feed additive of the present invention can be used as a feed additive containing a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included.
  • a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included
  • the animal feed additive containing the rice grasshopper extract of the present invention and the feed containing the same can be used as auxiliary ingredients such as amino acids, inorganic salts, vitamins, antibiotics, antimicrobials, antioxidants, antifungal enzymes, digestion and absorption enhancers, growth promoters, Can be used with the same material.
  • the feed additive may be administered alone to the animal in combination with other feed additives in the edible carrier.
  • the feed additives can also be easily administered as top dressing or they can be mixed directly with the animal feed or separately from the feed, in separate oral formulations, by injection or transdermal, or in combination with other ingredients.
  • a single daily dose or a divided daily dose can be used as is well known in the art.
  • the dosage form of the extract may be prepared in an immediate release or sustained release formulation in combination with a non-toxic pharmaceutically acceptable food carrier.
  • Such edible carriers may be solid or liquid, for example, corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol.
  • the dosage form of the extract may be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form.
  • a liquid carrier it may be in the form of a soft gelatin capsule, or a syrup or liquid suspension, emulsion or solution.
  • the dosage form may contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoting agents and the like.
  • the animal feed in which the rice grasshopper extract is included as a feed additive can be any protein-containing organic grain fraction commonly used to meet animal dietary needs. These protein-containing flours usually consist mainly of corn, soy flour or corn / soy flour mix.
  • the feed additive may be added to the animal feed by immersion, spraying or mixing.
  • the veterinary composition or feed additive of the present invention can be applied to the companion animal's diet.
  • the present invention also relates to a method for the prevention or treatment of fatty liver disease comprising the step of administering a rice grasshopper extract to a subject other than a human.
  • Such an individual includes all animals, including those with a possibility of fatty liver disease, including those suffering from fatty liver disease.
  • Liver cancer cell line (HepG 2) were purchased from ATCC (American Type Culture Collection). Streptomycin and cultured in a DMEM (Dulbecco's modified Eagle's medium ) containing the medium-liver cancer cell line (HepG 2) is 10% FBS, 1% penicillin. The cells were cultured at 37 ° C in a 5% CO 2 incubator. The cultured cells were divided into a number of cells (3 ⁇ 10 4 cells / 500 ⁇ l well) in a 24-well plate.
  • DMEM Dynabecco's modified Eagle's medium
  • a 0.1 M NaOH solution was used as a solvent at 70 ⁇ C, filtered using a 0.2 ⁇ filter, and then sterilized.
  • the concentration of each fatty acid prepared in (1) above was measured using a 5% (w / v) BSA solution containing no free fatty acid dissolved in the tertiary distilled water prepared in (2) 10 ml of a fatty acid storage solution was prepared so as to be 5 mM.
  • the 100 mM palmitate and 100 mM olate stock solutions prepared in 1) above were mixed with 165 ⁇ l (1.65 mM) of palmitate and 330 ⁇ l (3.3 mM) of oleate to prepare 9,505 ⁇ l of 5% w / v) dropwise dropwise to the BSA solution (vortexing). Thereafter, the mixture was cooled to room temperature, and then filtered with a 0.2 ⁇ m filter (the mixed solution was stable at -20 ° C. for 3 to 4 weeks).
  • the rice seedlings were extracted with 70% (v / v) ethanol to obtain an ethanol extract, and the ethanol extract was distilled under reduced pressure to obtain an ethanol extract.
  • Example 4 Assessment of the content of triglycerides using nile red (AdipoRed staining) assay
  • Nile Red H depot red
  • FFA free fatty acids
  • AdipoRed solution prepared by dissolving 300 ⁇ l of AdipoRed in 10 ml of PBS
  • 500 ⁇ l / well of AdipoRed solution was dispensed under the condition of 37 ° C., and shaken for 15 minutes under a dark condition at room temperature for 15 minutes Respectively.
  • the plates were wrapped with aluminum foil to minimize photobleaching of the dye during this process.
  • After the completion of the reaction it was applied to a spectrophotometer to measure excitation at 485 nm and emission at 572 nm.
  • Example 5 Determination of total triglyceride content and degree of lipid uptake according to the treatment of rice hull extract
  • liver cancer cell line (HepG 2) the change is going on by the processes of ethanol decreased cell viability and increase the amount of Caspase-3 expression in the treatment of the extract was found to byeomettugi.
  • Example 7 Weight change of animal model according to the administration of rice hull extract; Liver, abdominal subcutaneous fat, kidney fat tissue and small intestine fat tissue; Analysis of lipid biochemical indicators
  • C57bl / 6Jj mice (mice) of 10 weeks of age were used in this Example 7, and male C57bl / 6Jj mice were fed from BioLink (Eumsung, Korea) for 7 weeks and adapted to the laboratory environment for 3 weeks. Mice with good health status were used in the experiment.
  • mice were fed with solid feed (antibiotics-free, Samyang Feed Co.) and water until the day of the experiment and maintained the environment of temperature 23 ⁇ 2 °C, humidity 55 ⁇ 15% (AIN-76A diet) and water were freely supplied and adapted to the laboratory environment. Then, 10-week-old mice with a good health condition were kept in a dark room at 23 ⁇ 2 ° C, humidity 55 ⁇ 15%, and 12 hours intervals with light on (07: 00 ⁇ 19: 00) SPF (Specific Pathogen Free) environment.
  • solid feed antibiotics-free, Samyang Feed Co.
  • the experimental animals were divided into two groups: normal control group (Nor), control group (HFD, 60% fat), high fat diet group (100, 200mg / kg) (100 mg / kg). The water and the diet of each experimental group were fed freely, and the rice horticulture extract was orally administered for 14 weeks.
  • the body weights of the experimental animals were measured and recorded for 14 weeks at a constant time every week. After 14 weeks, the experimental animals were divided into liver tissue weight, abdominal subcutaneous fat, small intestine fat and retroperitoneal adipose tissue And the weight of adipose tissue was calculated after extraction.
  • the rice plant extract (MTG) of the present invention can reduce the liver tissue weight increased by the high fat diet
  • the liver tissue of the group that consumed both the high fat diet and the rice horticultural extract (MTG) The weight of the abdominal subcutaneous fat, kidney adipose tissue and small intestine adipose tissue increased in the high fat diet group (HFD) according to the high fat diet method.
  • HFD high fat diet group
  • the weight of abdominal subcutaneous fat, kidney adipose tissue and small intestine adipose tissue of mice decreased (Fig. 7).
  • ALT and AST which are indicators of liver function in plasma separated from each experimental animal after 14 weeks of rice grasshopper extract and milk seed, were measured by using triglyceride, total cholesterol, Low-density lipoprotein, free fatty acid, and blood sugar content were measured using a biochemical automatic analyzer (Hitachi-720, Hitachi Medical, Japan).
  • ALT and AST were significantly higher in high fat diet group and MTG group than high fat diet group (Fig. 8).
  • the blood glucose concentration in the serum was increased by the high fat diet (HFD), but the blood glucose concentration in the high fat diet and the rice horticultural extract (MTG) group was decreased statistically significantly compared to the high fat diet group (FIG. 10) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Insects & Arthropods (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif. Il a été confirmé que l'extrait d'Oxya chinensis, en tant qu'ingrédient actif de cette invention, réduit efficacement l'accumulation de triglycérides dans une lignée cellulaire du cancer du foie (HepG2) et, lors de administration, présente surtout des changements du poids corporel des modèles animaux, des changements du poids du foie, de la graisse sous-cutanée, du tissu adipeux rénal, et du tissu adipeux de l'intestin grêle, et des changements des indicateurs biochimiques lipidiques. De ce fait, la composition selon la présente invention peut être utilisée utilement en tant qu'aliments naturels fonctionnels, médicament ou additif alimentaire pour la prévention, le soulagement ou le traitement de la stéatose hépatique.
PCT/KR2018/007320 2017-06-30 2018-06-28 Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif Ceased WO2019004734A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170083131 2017-06-30
KR10-2017-0083131 2017-06-30
KR10-2017-0181811 2017-12-28
KR1020170181811A KR102041852B1 (ko) 2017-06-30 2017-12-28 벼메뚜기 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2019004734A2 true WO2019004734A2 (fr) 2019-01-03
WO2019004734A3 WO2019004734A3 (fr) 2019-03-28

Family

ID=64741735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007320 Ceased WO2019004734A2 (fr) 2017-06-30 2018-06-28 Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif

Country Status (1)

Country Link
WO (1) WO2019004734A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4753089B2 (ja) * 2004-12-20 2011-08-17 株式会社岡安商店 体内脂肪の分解促進作用を有する組成物及びそれを含有する食品又は食品配合剤
KR101648812B1 (ko) * 2013-12-27 2016-08-17 윤철호 벼메뚜기 성분을 포함하는 다이어트 식품 조성물 제조 방법
KR20180013204A (ko) * 2016-07-29 2018-02-07 농업회사법인 주식회사 디앤이이노베이션 메뚜기 에틸아세테이트 분획물을 유효성분으로 함유하는 간 기능 개선용 조성물

Also Published As

Publication number Publication date
WO2019004734A3 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
KR101944985B1 (ko) 지초 추출물을 유효성분으로 포함하는 근줄기세포로부터 근육세포로의 분화 촉진용 조성물, 근력 약화 관련 질환의 예방 또는 치료용 약제학적 조성물 및 운동수행 능력 향상용 건강기능식품 조성물
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
KR102456356B1 (ko) 락토바실러스 혼합균주를 유효성분으로 포함하는, 월경전 증후군 완화용 조성물
US10617732B2 (en) Composition including extract of Dolichos lablab Linne as active ingredient for preventing or ameliorating non-alcoholic fatty liver disease
JP2008174539A (ja) 紫色の馬鈴薯を使用した肥満患者用の健康機能食品
WO2019093739A1 (fr) Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique
WO2018117659A1 (fr) Composition pharmaceutique comprenant un extrait de levis pulverata indigo ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une maladie intestinale inflammatoire
KR100919852B1 (ko) 해방풍 추출물을 유효성분으로 함유하는 부종 또는 피부염예방 및 치료용 조성물
WO2020059995A1 (fr) Composition de boisson diététique pour la prévention d'effets nocifs pour le foie provoqués par l'alcool tout en fournissant un excellent remède pour les effets secondaire causés par l'alcool
KR102085577B1 (ko) 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
KR101392715B1 (ko) 의이인탕을 유효성분으로 함유하는 비만의 예방, 개선 또는 치료를 위한 조성물
KR102041852B1 (ko) 벼메뚜기 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
WO2024080715A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la stéatose hépatique contenant un extrait de glycine max en tant que principe actif
WO2021201532A1 (fr) Composition de prévention, de soulagement ou de traitement du syndrome ménopausique chez la femme, contenant un extrait de rosa rugosa en tant que principe actif
WO2023038258A1 (fr) Nouvelle souche lactobacillus gasseri lm1065 issue du lait maternel, et composition pour soulager le syndrome prémenstruel comprenant ladite souche ou son produit de culture
KR101913828B1 (ko) 지초 추출물을 유효성분으로 포함하는 근줄기세포로부터 근육세포로의 분화 촉진용 조성물, 근력 약화 관련 질환의 예방 또는 치료용 약제학적 조성물 및 운동수행 능력 향상용 건강기능식품 조성물
US20230000940A1 (en) Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof
WO2019004734A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif
WO2019083264A1 (fr) Composition pour prévenir, soulager ou traiter des maladies du foie, contenant un produit fermenté d'extrait de germe de ginseng vieilli en tant que substance active
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
WO2019004733A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif
KR100539457B1 (ko) 괴각 추출물을 포함하는 고지혈증, 동맥경화증 및지방간의 예방 및 치료용 조성물
KR101688116B1 (ko) 여주 추출물을 유효성분으로 포함하는 남성 갱년기 치료 및 예방용 조성물
KR20190083071A (ko) 모과나무 잎 추출물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
JP2017222715A (ja) 経口組成物、脂肪細胞分化抑制剤および飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18824360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18824360

Country of ref document: EP

Kind code of ref document: A2